My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every time.
Start Research-backed Investing ...in less than a minute.
BSE: 540596 | NSE: ERIS | Pharmaceuticals & Drugs | Small Cap
1. Is Eris Lifesciences Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Eris Lifesciences Ltd is a good quality company.
2. Is Eris Lifesciences Ltd undervalued or overvalued?
The key valuation ratios of Eris Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Eris Lifesciences Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Eris Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | |||
| ROCE % ⓘ | 68.9% | 46.1% | 38.4% | 45.9% | 51.6% | 30.7% | 23.4% | 22.3% | 24.7% | 23.3% | - | ||
| Value Creation Index ⓘ | 4.1 | 2.4 | 1.8 | 2.4 | 2.7 | 1.3 | 0.7 | 0.7 | 0.8 | 0.7 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 393 | 509 | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,566 | ||
| YoY Gr. Rt. % | - | 29.5% | 7.2% | 9.4% | 25.5% | 14.2% | 14.8% | 9.4% | 12.8% | 11.2% | - | ||
| Adj EPS ⓘ | 4,250.7 | 4,936.6 | 6,320.3 | 9,569 | 16.7 | 20.2 | 21 | 21.6 | 26 | 30 | 29.2 | ||
| YoY Gr. Rt. % | - | 16.1% | 28% | 51.4% | -99.8% | 20.5% | 4.3% | 2.7% | 20.5% | 15.3% | - | ||
| BVPS (₹) ⓘ | 7,687.5 | 12,817.5 | 19,278.6 | 21,711.8 | 41.3 | 62.6 | 83.6 | 95.3 | 115.8 | 140.3 | 156.4 | ||
| Adj Net Profit ⓘ | 58.5 | 67.9 | 86.9 | 132 | 230 | 277 | 289 | 293 | 353 | 408 | 397 | ||
| Cash Flow from Ops. ⓘ | 38 | 89.6 | 90.1 | 131 | 200 | 235 | 223 | 271 | 375 | 378 | - | ||
| Debt/CF from Ops. ⓘ | 0.1 | 0 | 0 | 0 | 0 | 1.6 | 0.8 | 0 | 0 | 0.1 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 14.7% | 12.4% | 11.1% | 11.2% | ||||||||
| Adj EPS ⓘ | -42.3% | 12.4% | 12.6% | 15.3% | ||||||||
| BVPS ⓘ | -35.9 | 27.7 | 18.8 | 21.1 | ||||||||
| Share Price | - | -6.4% | 15.8% | -19% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | ||
| Return on Equity % ⓘ | 75.9 | 48 | 39.2 | 46.5 | 53.1 | 38.8 | 28.7 | 24 | 24.6 | 23.4 | 19.7 | |
| Op. Profit Mgn % ⓘ | 22 | 19.5 | 22.3 | 28.8 | 35.9 | 37.7 | 35.2 | 34.7 | 35.6 | 36.3 | 32.9 | |
| Net Profit Mgn % ⓘ | 14.9 | 13.4 | 15.9 | 22.3 | 30.7 | 32.5 | 29.5 | 27.3 | 29.1 | 30.2 | 25.4 | |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0.4 | 0.2 | 0 | 0 | 0 | - | |
| Working Cap Days ⓘ | 69 | 71 | 71 | 68 | 77 | 101 | 118 | 130 | 136 | 145 | 0 | |
| Cash Conv. Cycle ⓘ | 14 | 10 | 8 | 12 | 11 | -4 | -4 | 7 | 14 | 13 | 0 | |
Sales growth is growing at healthy rate in last 3 years 11.10%
Net Profit is growing at healthy rate in last 3 years 12.56%
Sales growth is good in last 4 quarters at 20.02%
Return on Equity has declined versus last 3 years average to 19.70%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 29.2 | 29.2 |
| TTM Sales (₹ Cr.) | 1,276 | 1,566 |
| BVPS (₹.) ⓘ | 156.8 | 156.4 |
| Reserves (₹ Cr.) ⓘ | 2,119 | 2,114 |
| P/BV ⓘ | 3.65 | 3.65 |
| PE ⓘ | 19.60 | 19.54 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 550.90 / 749.85 |
| All Time Low / High (₹) | 341.05 / 896.00 |
| Market Cap (₹ Cr.) | 7,779 |
| Equity (₹ Cr.) | 13.6 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 36.2 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.
The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers.
The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists.
Business area of the company
The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.
History and milestones
Download APP
